This is a medication used to treat certain types of lung cancer. It works by blocking specific proteins that help cancer cells grow. It's a targeted therapy, meaning it attacks cancer cells while trying to spare healthy cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Xalkori (Crizotinib) for Non-Small Cell Lung Cancer?
Crizotinib, sold as Xalkori, is a targeted cancer medicine taken by mouth. It is used only for cancers driven by a specific genetic change, so the tumor has to be tested first. In adults, its main use is non-small cell lung cancer (NSCLC) that has spread and carries a change in either the ALK gene (anaplastic lymphoma kinase) or the ROS1 gene, confirmed by an FDA-approved test. Crizotinib is also approved for two rarer ALK-positive cancers: anaplastic large cell lymphoma (ALCL), a type of lymphoma, in children 1 year and older and young adults when it has come back or not responded to treatment; and inflammatory myofibroblastic tumor (IMT), an uncommon soft-tissue tumor, in adults and children 1 year and older when surgery is not an option or the tumor has returned. Crizotinib has been available since 2011. For ALK-positive lung cancer that has not yet had targeted treatment, newer ALK inhibitors such as Alecensa (alectinib), Alunbrig (brigatinib) and Lorbrena (lorlatinib) have proved more effective, including against cancer that has spread to the brain, and are generally preferred. Crizotinib remains an option in some situations, and for ROS1-positive lung cancer it is one of several targeted medicines that can be used.
Kinases are proteins that switch on growth signals inside cells. In ALK-positive and ROS1-positive cancers, part of the ALK or ROS1 gene has broken off and fused with another gene. The resulting fusion protein stays switched on, sending a constant signal that helps the cancer cells multiply and survive. Crizotinib attaches to these overactive kinases (ALK, ROS1 and a related one called MET) and blocks their signal. Cancers that depend on that signal often shrink or stop growing. This is why the test result matters: in a cancer without one of these changes, the drug has no comparable target. Over time, many cancers find another way around the block and start growing again, which is when doctors look at the next treatment.
Crizotinib comes as capsules and as oral pellets. Adults usually take it twice a day, with or without food, and continue for as long as it keeps the cancer under control and side effects are manageable. Children and young adults are dosed by body size. If side effects become a problem, the care team may pause treatment or lower the dose rather than stop it outright. Capsules should be swallowed whole, not chewed, crushed or split. The pellets, made for people who cannot swallow capsules, come inside a shell that is opened, not swallowed: the pellets are emptied into the mouth or onto a spoon or medicine cup and followed with water so all of them go down. They should not be chewed or crushed either. If a dose is missed, take it when remembered unless the next dose is due within 6 hours, in which case skip it. If you vomit after a dose, do not take another; wait for the next scheduled one.
Vision changes are among the most common effects, usually starting in the first week: blurred vision, flashes of light, light sensitivity or new floaters. In adults with lung cancer, nausea, diarrhea, vomiting, constipation, swelling of the hands, feet or face, tiredness, poor appetite, dizziness, and numbness or tingling in the hands or feet are also common. Skin can burn more easily in the sun. Many of these settle or can be managed, so they are worth raising rather than enduring. Avoid driving or operating machinery when vision changes, dizziness or tiredness are affecting you. Children and young adults treated for ALCL or IMT are more likely to have severe nausea, vomiting, diarrhea and mouth sores. Anti-nausea medicine is usually given before and during treatment, and problems swallowing, ongoing vomiting or diarrhea should be reported to the care team right away because dehydration can develop. A few serious effects need prompt attention. Crizotinib can cause liver injury, rarely fatal, most often in the first two months. Yellow skin or eyes, dark tea-colored urine, pain on the right side of the belly, unusual tiredness, itching or easier bleeding or bruising should be reported right away. Lung inflammation (pneumonitis), usually within the first three months, can be life-threatening; because it can feel like the cancer itself, new or worsening shortness of breath, cough or fever should be reported right away. Crizotinib commonly slows the heart rate, so dizziness, fainting or an abnormal heartbeat also call for a prompt call. Severe vision loss is rare but needs urgent contact with the care team and an eye specialist.
Crizotinib can slow the heart and lengthen the QT interval, a measure of the heart's electrical recharging seen on an ECG (electrocardiogram); a long QT raises the risk of a dangerous irregular rhythm. It is avoided in people born with long QT syndrome. Because crizotinib already slows the heart, combining it with other heart-slowing medicines is avoided where possible: beta-blockers and the calcium channel blockers diltiazem and verapamil (common blood pressure and heart-rhythm medicines), clonidine (a blood pressure medicine) and digoxin (a heart failure and heart-rhythm medicine). The same applies to medicines that prolong QT, which a pharmacist can check for. Anyone with heart failure, a slow heart rate or low potassium or magnesium may need ECG and blood checks. The body clears crizotinib through a liver enzyme called CYP3A. Strong blockers of that enzyme, such as the antifungals ketoconazole and itraconazole, raise crizotinib levels and side effects; grapefruit and grapefruit juice do the same and should be avoided. Strong enzyme boosters, such as the antibiotic rifampin, lower crizotinib levels and can make it less effective. Crizotinib can in turn raise levels of some other medicines. Tell the care team and pharmacist about every prescription, over-the-counter medicine and supplement, including heart and blood pressure medicines. Crizotinib can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 45 days after the last dose, and men with partners who could become pregnant should use condoms during treatment and for 90 days afterward. Breastfeeding is not advised during treatment or for 45 days after. Crizotinib may also reduce fertility in both women and men, which is worth discussing before starting if future children matter.
Before starting, the tumor is tested to confirm the ALK or ROS1 change. Treatment then becomes a routine of capsules or pellets at home and regular check-ins. Liver blood tests are done every two weeks for the first two months and then monthly, blood counts (which check for low white cells that raise infection risk, so fever should be reported) weekly in the first month and then at least monthly, with heart rate and blood pressure checked along the way. Children and young adults with ALCL or IMT also have eye exams before or soon after starting and every three months. Scans every few months show whether the cancer is shrinking or stable. In the main trial for previously untreated ALK-positive lung cancer, about three in four people had their tumors shrink, and half of the people went about 11 months or longer before the cancer grew, compared with 7 months on chemotherapy. Responses vary widely, and some people stay on crizotinib much longer. When the cancer starts growing again, it has usually found a way around the drug. That is not the end of targeted treatment: for ALK-positive lung cancer, newer ALK inhibitors often work after crizotinib, and a new biopsy or blood test may help guide the choice.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Xalkori (Crizotinib), what you've noticed, or ask the community a question.